Therapeutic Area: Endocrinology Product Name: HMS5552
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.